Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.63 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.62 |
| ▸ | KLK7 | P49862 | 1/20 | 0.62 |
| ▸ | PPARG | P37231 | 4/20 | 0.58 |
| ▸ | ACE | P12821 | 1/20 | 0.56 |
| ▸ | SYK | P43405 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 4/20 | 0.54 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | PPARD | Q03181 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344669 | 1.00 | PPARA (0.63) | PPARAKLK5KLK7PPARGACE | |
| SCHEMBL84710 | 1.00 | PPARA (0.63) | PPARAKLK5KLK7PPARGACE | |
| SCHEMBL10585294 | 0.92 | KLK5 (0.65) | PPARAKLK5KLK7PPARGACE | |
| SCHEMBL12585497 | 0.92 | KLK5 (0.65) | PPARAKLK5KLK7PPARGACE | |
| SCHEMBL9943562 | 0.92 | KLK5 (0.65) | PPARAKLK5KLK7PPARGACE | |
| SCHEMBL4370045 | 0.92 | KLK5 (0.65) | PPARAKLK5KLK7PPARGACE | |
| SCHEMBL9943561 | 0.92 | KLK5 (0.65) | PPARAKLK5KLK7PPARGACE | |
| SCHEMBL5870038 | 0.91 | KLK5 (0.64) | PPARAKLK5KLK7PPARGACE | |
| SCHEMBL14300984 | 0.91 | KLK5 (0.64) | PPARAKLK5KLK7PPARGACE | |
| SCHEMBL14300985 | 0.91 | KLK5 (0.64) | PPARAKLK5KLK7PPARGACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114105823-A | Fluorescent probe and preparation method and application thereof | 长江大学 | 2022-03-01 | — | — | CN | claimed |
| CN-109913204-A | A kind of active near infrared fluorescent probe of detection marker of inflammation and its synthetic method | 山东师范大学 | 2019-06-21 | — | — | CN | claimed |
| EP-0549727-A1 | CARBOXYLIC ACID ESTERS OF RAPAMYCIN | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-07-07 | — | — | EP | claimed |
| US-5130307-A | Antibody inhibitors; treating organ graft rejection, fungal infections; antiinflammatory agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-07-14 | — | — | US | claimed |
| WO-1992005179-A1 | CARBOXYLIC ACID ESTERS OF RAPAMYCIN | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-04-02 | — | — | WO | claimed |
| EP-4688789-A1 | MACROCYCLIC RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250340574-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-11-06 | — | — | US | disclosed |
| CN-119522215-A | TEAD inhibitors and methods of use | 思博睿生物探索公司 | 2025-02-25 | — | — | CN | disclosed |
| EP-4504739-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2024211663-A9 | MACROCYCLIC RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2025-01-30 | — | — | WO | disclosed |
| EP-4496789-A1 | TEAD INHIBITORS AND METHODS OF USE | Sporos Biodiscovery, Inc. (US) | 2025-01-29 | — | — | EP | disclosed |
| US-20250025438-A1 | Derivative of aspartic acid and use thereof in treatment of metabolic diseases such as hepatic fibrosis and non-alcoholic hepatitis | SHENZHEN JINGTAI TECHNOLOGY CO., LTD. (CN) | 2025-01-23 | — | — | US | disclosed |
| WO-1996029327-A1 | TRYPSIN AND THROMBIN INHIBITORS | NOVARTIS AG (CH) | 1996-09-26 | — | — | WO | disclosed |
| US-5491166-A | ENZYME INHIBITORS, VIRICIDES | ELI LILLY AND COMPANY (US) | 1996-02-13 | — | — | US | disclosed |
| US-5430024-A | Peptides bearing N-terminal amidino moieties and their use as inhibitors of platelet aggregation | HOFFMANN-LA ROCHE INC. (US) | 1995-07-04 | — | — | US | disclosed |
| EP-0604186-A1 | Inhibitors of HIV protease useful for the treatment of aids | ELI LILLY AND COMPANY (US) | 1994-06-29 | — | — | EP | disclosed |
| US-5302600-A | Inducing immunosuppression; antiinflammatory agents, antifungal, antitumor and antiproliferative agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-04-12 | — | — | US | disclosed |
| US-5273982-A | An amidinoaryleneamidoalkylpiperazinyleneacetic acid | HOFFMANN-LA ROCHE INC. (US) | 1993-12-28 | — | — | US | disclosed |
| US-5256790-A | Antibiotic | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-10-26 | — | — | US | disclosed |
| US-5130307-A | Antibody inhibitors; treating organ graft rejection, fungal infections; antiinflammatory agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340574-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | PPARA 1689/4885KLK5 4100/4885KLK7 4265/4885 |
| US-20250025438-A1 | Derivative of aspartic acid and use thereof in treatment of metabolic diseases such as hepatic fibrosis and non-alcoholic hepatitis | GOT1, GOT2, GLS2 | PPARA 211/4885KLK5 1770/4885KLK7 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.